Multiple machine learning-based integrations of multi-omics data to identify molecular subtypes and construct a prognostic model for HNSCC.

Journal: Hereditas
PMID: 39910672

Abstract

BACKGROUND: Immunotherapy has introduced new breakthroughs in improving the survival of head and neck squamous cell carcinoma (HNSCC) patients, yet drug resistance remains a critical challenge. Developing personalized treatment strategies based on the molecular heterogeneity of HNSCC is essential to enhance therapeutic efficacy and prognosis.

Authors

  • Xiaoqin Luo
    Department of Geriatrics, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
  • Chao Li
    McGill University Health Centre, McGill Adult Unit for Congenital Heart Disease Excellence, Montreal, Québec, Canada.
  • Gang Qin
    School of Physics and Electronic Engneering, Zhoukou Normal University, Zhoukou 466001, China.

Keywords

External Resources

Popular Topics
Recent Journals